Close Menu

More articles about Metabolic Disease

LabCorp and TACHC will use data analytics and clinical decision support tools to improve the care of patients with chronic kidney disease and diabetes.

The firm anticipates that in 2019 it will begin clinical trials for a comprehensive metabolic panel for use on its point-of-care platform.

The National Institutes of Health Commercial Accelerator Program helps small healthcare and life science companies bring their products to market.

The funding will be directed at conducting clinical trials for its technology based on activity sensors to detect human diseases and monitor drug responses.

The IVD kit is for use with a mass spectrometer and quantitatively measures and evaluates traditionally screened amino acids and measures up to 51 analytes.

The test is US Food and Drug Administration approved for detecting recent hyperglycemia and hyperglycemic excursions in patients with diabetes.

The biomarker profiling project is expected to enable a better understanding of how lifestyle, environment, and genetics combine to cause diseases.

Seksui's test is used in clinical labs to measure the percent concentration of HbA1c or the HbA1c fraction mmol/mol in human venous whole-blood and hemolysate.

The Dip.io technology uses a smartphone's camera to capture high-quality images of a patient's urinalysis results and immediately send it off for clinical diagnosis.

The trial, part of a multiyear effort to standardize HbA1c testing in labs, will be repeated annually with more labs participating and more countries represented.

The expanded clearance includes use of the test to assess a patient's risk of developing diabetes. The assay was cleared to run on the Afinion AS100 Analyzer.

The study found that for some patients the standard practice of performing a second confirmatory blood test is not necessary, which could streamline care.

Patia will offer the assay, which uses mass spectrometry to measure proteins to predict risk of diabetic kidney disease, as a laboratory-developed test.

The deal begins commercialization of Emosis' first test for heparin-induced thrombocytopenia in at least 36 countries that recognize CE marking.

Metafora is developing a blood test to help with early diagnosis of De Vivo disease, a metabolic disorder associated with glucose transport deficiency.

PrismHealthDx will offer the assay, which uses mass spectrometry to measure proteins to predict risk of diabetic kidney disease, as a laboratory-developed test.

UK researchers found that just 22 percent of screening recommendations for rare newborn diseases were based on systematic reviews of available evidence.

The companies will comarket an offering that includes Siemens Healthineers' DCA Vantage Analyzer for HbA1c testing and Clinitek Status + Urine Chemistry Urine Analyzer.

The effort could lead to Metafora's flow cytometry-based assay becoming the standard of care for diagnosing the disease in France.

The collaboration aims to eliminate barriers to testing for chronic kidney disease by standardizing the method for testing for the condition, thereby improving the comparison of test results between labs.

Pages